中慧生物
Ab&B Bio-Tech

Ab&B Bio-Tech CO., LTD. JS
江蘇中慧元通生物科技股份有限公司

(A joint stock company established in the People's Republic of China with limited liability)

(Stock Code: 2627)

VOLUNTARY ANNOUNCEMENT

This announcement is made by Ab&B Bio-Tech CO., LTD. JS (the "**Company**", together with its subsidiary, the "**Group**") on a voluntary basis to provide the shareholders of the Company (the "**Shareholders**") and potential investors with the information on the latest developments of the Company.

The board of directors of the Company (the "**Board**") is pleased to announce that, according to the announcement issued by the National Healthcare Security Administration on August 12, 2025, the preliminary list of the National Commercial Health Insurance Innovative Drug List for this year includes the only vaccine product – quadrivalent subunit influenza vaccine.

The Group's core product, quadrivalent subunit influenza vaccine under the brand name Huierkangxin (慧爾康欣), received New Drug Application (NDA) approval from the National Medical Products Administration (NMPA) of China in May 2023 for use in individuals aged three years and above (at a specification of 15μg/0.5ml in terms of viral hemagglutinin concentration). As of July 21, 2025, it was the first and only quadrivalent subunit influenza vaccine approved in China. The quadrivalent subunit influenza vaccine is designed to offer broad protection against two influenza A viruses (H1N1 and H3N2 subtypes) and two influenza B viruses (Yamagata and Victoria lineages). This product represents a significant upgrade from traditional split-virion vaccines, offering comprehensive protection, high antigen purity and low risk of adverse reactions.

This announcement is published on a voluntary basis by the Company. There is no assurance that the Group will be able to ultimately develop and market its quadrivalent subunit influenza vaccine for all intended age groups successfully. **Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.**

By order of the Board
Ab&B Bio-Tech CO., LTD. JS
Mr. AN Youcai
Executive Director, chairman of the Board and general manager

Hong Kong, August 13, 2025

As at the date of this announcement, the Board comprises: (i) Mr. AN Youcai, Ms. LI Runxiang and Mr. HE Yiming as executive Directors; (ii) Mr. CHENG Qianwen, Mr. YU Jianlin and Mr. DU Mu as non-executive Directors; and (iii) Mr. LI Xiangming, Ms. LI Xiaoqing and Mr. CHEN Chengbei as independent non-executive Directors.